This strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines, and extending US commercial reach, it states.

The investment was made through a new issue of shares. Following the transaction, James Gale, Managing Director at Signet Healthcare Partners, will join the NorthX Biologics Board of Directors.

“We are delighted to welcome Signet Healthcare Partners as a shareholder. With their significant experience in pharma services, they are an excellent complement to NorthX Biologics and are well positioned to support our journey,” says Janet Hoogstraate, Chief Executive Officer of NorthX Biologics.

Flerie remains the majority shareholder following the transaction. Terms were not disclosed.